EGF vs rhPDGF-BB
Head-to-head comparison of EGF (Human Epidermal Growth Factor) and rhPDGF-BB (Recombinant Human Platelet-Derived Growth Factor-BB) — benefits, dosing, side effects, research data, and where to buy.
| Property | EGF | rhPDGF-BB |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Human Epidermal Growth Factor | Recombinant Human Platelet-Derived Growth Factor-BB |
| Molecular Weight | 6.0 kDa | 24.8 kDa |
| Half-Life | minutes | minutes |
| Amino Acids | 53 | 109 per chain (homodimer) |
| Typical Dose | 0.04–0.1 mg/cm²/day | 100 µg/g gel once daily |
| Route | Topical | Topical |
| Purity | ≥98% | ≥98% |
| Studies Count | 650 | 400 |
| Research Status | Clinical | Clinical |
EGF Benefits
- ✓re-epithelialization
- ✓fibroblast activation
- ✓angiogenesis support
- ✓faster ulcer closure
rhPDGF-BB Benefits
- ✓cell migration
- ✓fibroblast proliferation
- ✓collagen deposition
- ✓diabetic ulcer healing
EGF Dosing
Topical daily|0.04–0.1 mg/cm²|short courses until granulation/closure
rhPDGF-BB Dosing
Topical once daily|apply to clean wound bed|continue until complete granulation/closure
EGF Side Effects
- ⚠local irritation
- ⚠erythema
- ⚠theoretical hyperproliferation
- ⚠pain at site
rhPDGF-BB Side Effects
- ⚠local erythema
- ⚠pain
- ⚠edema
- ⚠theoretical tumor-promoting risk
Research Overview
EGF
Human and animal studies show EGF can accelerate epithelial migration and wound closure, especially in burns, ulcers, and mucosal injury. Its best evidence is for topical or local delivery because systemic exposure is brief and the effect is highly localized.
rhPDGF-BB
rhPDGF-BB has one of the strongest clinical wound-healing datasets among growth factors and is best known for chronic diabetic foot ulcers. Its efficacy is tied to chemotaxis and mitogenesis in fibroblasts, smooth muscle cells, and macrophage-lineage cells.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.